GlaxoSmithKline Signs Contract for its Pandemic Flu Vaccine with UK Government

GlaxoSmithKlineGlaxoSmithKline (GSK) today announced that it has entered into an agreement with the UK Government to provide its pandemic influenza vaccine in the event of a flu pandemic. It is one of the largest contracts signed by GSK to date for its proprietary adjuvanted pandemic flu vaccine.

As part of an Advance Supply Agreement, GSK has committed to make the necessary preparations to supply its pandemic influenza vaccine as soon as possible after a pandemic outbreak has been declared.ntracts signed by GSK to date for its proprietary adjuvanted pandemic flu vaccine. GSK plans to supply a 'tailored' pandemic vaccine as and when the pandemic strain is identified and made available by the World Health Organisation (WHO).

Andrew Witty, President GSK Pharmaceuticals Europe, said: "This agreement underlines GSK's commitment to supporting the UK Government in its plans against a possible influenza pandemic. Vaccines are considered to be the single most important intervention for preventing influenza infection and reducing spread of the disease. They are a critical component of any response plan aimed at reducing the potentially devastating effects of an influenza pandemic. GSK believes that securing a pandemic vaccine supply is an important step towards full pandemic preparedness and ultimately the protection of the British public."

The WHO has stated that an influenza pandemic poses a serious global public health threat with substantial estimated morbidity and mortality. GSK is committed to supporting governments and health authorities around the world in planning to respond to a global influenza pandemic, both prior to an outbreak and in the event one is officially declared. This latest agreement with the UK Government follows recent supply agreements signed with the Swiss, Danish and Icelandic governments. GSK has applied for registration of its pandemic vaccine in January, 2007 to the EMEA.

Professor John Oxford, Professor of Virology, Queen Mary's School of Medicine, St Bartholomew#s and the Royal London Hospitals, and Scientific Director of Retroscreen Virology Ltd said: "This announcement by the UK Government is very good news. The World Health Organisation and experts across the globe agree that an influenza pandemic is likely to occur, but cannot predict when. Despite this uncertainty, there is still the opportunity to be thoroughly prepared. This agreement is part of the preparation needed to protect the UKpopulation when an influenza pandemic eventually strikes."

The pandemic vaccine utilises GSK's proprietary adjuvant system technology which has been shown to reduce the amount of antigen required to elicit a seroprotective response – the so-called 'antigen-sparing' effect. This allows a greater number of vaccine doses to be produced when antigen availability is likely to be limited, thereby offering the potential for vaccination to more people in the event of a flu pandemic. In recent pre-clinical trials the adjuvanted vaccine has shown the potential to recognize different H5N1 viruses and to induce cross-protection.

Since 2000, GSK has made substantial progress in its pandemic influenza vaccine development programme and continues to investigate ways to further improve vaccination strategies to respond to a pandemic. To this end, more than $2 billion has already been invested by GSK in combating avian flu; increasing GSK's production capacity for influenza vaccines and GSK's anti-viral flu treatment Relenza® (zanamivir), and in ensuring the continuity of critical business operations and processes, to safeguard the continued supply of critical medicines.

About GlaxoSmithKline
GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline at www.gsk.com

Most Popular Now

FDA grants priority review to Roche's cancer immun…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) a...

Kymriah® (tisagenlecleucel), first-in-class CAR-T …

Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication ...

Daily aspirin linked to higher risk in men

Men who take once-daily aspirin have nearly double the risk of melanoma compared to men who are not exposed to daily aspirin, reports a new Northwestern Medicine study. W...

New leads on treating dementia and Alzheimer's

A new research study by scientists in Australia and the US provides an explanation for why clinical trials of drugs reducing proteins in the brain that were thought to ca...

Roche reports a strong start in 2018

Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that in the first three months of 2018, Group sales rose 6% to CHF 13.6 billion. Sales in the Pharmaceuticals Division in...

To treat pain, you need to treat the patient

People in chronic pain are some of the most difficult patients to treat. They have complex circumstances that medicine can't always remedy. Pain can be amplified, by depr...

Novo Nordisk participates in new research project …

Within the newly started European research project Hypo-RESOLVE, 23 leading international players from academia, industry and civil society have joined forces to find bet...

Chemical octopus catches sneaky cancer clues, trac…

Cancer drops sparse chemical hints of its presence early on, but unfortunately, many of them are in a class of biochemicals that could not be detected thoroughly, until n...

Alcon Cares Project 100 commits to reducing catara…

Alcon, the global leader in eye care and a division of Novartis, has announced Alcon Cares Project 100, which aims to reduce cataract blindness by providing equipment to ...

FDA approves novel preventive treatment for migrai…

The U.S. Food and Drug Administration today approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. The treatment is given by once-monthly se...

First clues to the causes of multiple sclerosis

Multiple sclerosis, which affects 1 in 1,000 people, is frequently characterised by relapses associated with variable functional impairments including among others vision...

Doctors in US and Canada launch sweeping pharmaceu…

The skyrocketing cost of prescription drugs is one of the biggest concerns for American voters. However, in his proposal last Friday, President Donald Trump failed to off...